Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-2438 in KRAS G12C mutant advanced solid tumors
NCT05485974Phase 1Active, not recruiting
- Sponsor
- HUYABIO International, LLC
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sosimerasib in solid tumor (advanced stage), sponsored by HUYABIO International, LLC. Primary endpoints: Maximum Tolerated Dose at 36 months, Recommended Phase 2 Dose at 36 months and 2 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
sosimerasib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05485974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485974.